Fundz

Merck To Acquire Acceleron Pharma Inc.

PUBLIC · MRKSep 30, 2021

Acquiring Company

Merck

RahwayManufacturingBiotechnologyHealthcareHealth Care

Description

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Acceleron Pharma Inc. (Nasdaq: XLRN), a publicly traded biopharmaceutical company, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Acceleron for $180 per share in cash for an approximate total equity value of $11.5 billion.

Other recent acquisitions in Healthcare and Manufacturing

Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.

Who to call at Merck, and when

When Merck changes hands, the new owners review vendors, systems and leadership. That is when the door opens.

  • An alert the day Merck raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Merck, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Merck. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Merck

Location

126 East Lincoln Avenue

Rahway, New Jersey, United States

About

For over 130 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten people and animals – including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases – as we aspire to be the premier research-intensive biopharmaceutical company in the world. For more information, visit www.merck.com and connect with us on Twitter, Facebook, Instagram, YouTube and LinkedIn.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Merck makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Peter
Likely contact at this company
••••••••@••••••••

See Peter's verified email →

Pranav
Senior decision-maker at this company
••••••••@••••••••

See Pranav's verified email →

Keith
Senior decision-maker at this company
••••••••@••••••••

See Keith's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Merck's next move

Learn about Strategic plan

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.